MX9306494A - POLYPEPTIDES Ó - SUBSTITUTES THAT HAVE THERAPEUTIC ACTIVITY. - Google Patents

POLYPEPTIDES Ó - SUBSTITUTES THAT HAVE THERAPEUTIC ACTIVITY.

Info

Publication number
MX9306494A
MX9306494A MX9306494A MX9306494A MX9306494A MX 9306494 A MX9306494 A MX 9306494A MX 9306494 A MX9306494 A MX 9306494A MX 9306494 A MX9306494 A MX 9306494A MX 9306494 A MX9306494 A MX 9306494A
Authority
MX
Mexico
Prior art keywords
useful
substitutes
polypeptides
therapeutic activity
dysfunction
Prior art date
Application number
MX9306494A
Other languages
Spanish (es)
Inventor
Regionald Richarrdson
David Christopher Horwell
William Howson
John Hughes
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MX9306494A publication Critical patent/MX9306494A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los compuestos de la invención son mono-, di-, tri-. tetra- y petapéptidos Ó-sustituidos útiles en el tratamiento de la obesidad, ansiedad, úlceras gastrointestinales, dolor, ataques e inflamación. También son útiles para bloquear la reacción provocada por la eliminación del uso de drogas o alcohol reducir la secreción del ácido gástrico. Además son útiles como agentes en la hipertensión, deficiencia cardiaca, ataque, disfunciones cognositivas, mejorada de la memoria, espástico, depresión, diabetes, cáncer, asma, disfunción, de la vejiga, psicosis y artritis y/o dolor inflamatorio. También se incluyen las composiciones farmacéuticas, los intermediarios novedosos y los procedimientos.The compounds of the invention are mono-, di-, tri-. tetra- and Ó-substituted petapeptides useful in the treatment of obesity, anxiety, gastrointestinal ulcers, pain, seizures and inflammation. They are also useful in blocking the reaction caused by eliminating the use of drugs or alcohol, reducing gastric acid secretion. Furthermore they are useful as agents in hypertension, heart failure, attack, cognitive dysfunction, memory enhancement, spastic, depression, diabetes, cancer, asthma, dysfunction, bladder, psychosis and arthritis and / or inflammatory pain. Pharmaceutical compositions, novel intermediates, and procedures are also included.

MX9306494A 1992-10-19 1993-10-19 POLYPEPTIDES Ó - SUBSTITUTES THAT HAVE THERAPEUTIC ACTIVITY. MX9306494A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96316992A 1992-10-19 1992-10-19
US13169393A 1993-10-08 1993-10-08

Publications (1)

Publication Number Publication Date
MX9306494A true MX9306494A (en) 1994-06-30

Family

ID=26829720

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9306494A MX9306494A (en) 1992-10-19 1993-10-19 POLYPEPTIDES Ó - SUBSTITUTES THAT HAVE THERAPEUTIC ACTIVITY.

Country Status (3)

Country Link
AU (1) AU5359694A (en)
MX (1) MX9306494A (en)
WO (1) WO1994009031A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735687B1 (en) * 1995-06-21 1997-08-14 Sederma Sa NEW SLIMMING COSMETIC COMPOSITIONS
CA2784748A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
JPWO2015083816A1 (en) * 2013-12-06 2017-03-16 国立大学法人京都大学 Novel NK3 receptor agonist

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE914334A1 (en) * 1990-12-17 1992-06-17 Black James Foundation Tetrapeptide derivatives and analogues
EP0668770A1 (en) * 1991-04-24 1995-08-30 Warner-Lambert Company $g(a)-SUBSTITUTED POLYPEPTIDES HAVING THERAPEUTIC ACTIVITY

Also Published As

Publication number Publication date
WO1994009031A1 (en) 1994-04-28
AU5359694A (en) 1994-05-09

Similar Documents

Publication Publication Date Title
NI200700010A (en) MODULATORS OF ALFA 7 ACETILCOLINE NICOTINICA RECEPTORS AND THERAPEUTIC USES
ECSP034810A (en) DERETADOS HETEROCICLILALCOXI-, -ALQUILTIO- Y - ALQUILAMINOBENZAZOL SUCH AS LIGANDOS 5-HIDROXITRIPTAMINA-6
GT200100014A (en) AMIDA COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINASES, AND THEIR INSTRUCTIONS FOR USE.
PT1315504E (en) 1-ALPHA-HYDROXY-2-METHYLENE-19-NOR-HOMOPREGNACALCIFEROL AND ITS THERAPEUTIC APPLICATIONS
MX9300977A (en) HETEROBICICLIC COMPOUNDS.
AR048912A1 (en) ANTI-NOGO IMMUNOGLOBULINS
ECSP055681A (en) NEW TRIAZOL COMPOUNDS AS INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF)
CU23029A3 (en) BENZOPIRAN REPLACED ANALOGS FOR THE TREATMENT OF INFLAMMATION
UY29796A1 (en) NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS
PA8571001A1 (en) 2- (2,6-DICLOROPHENYL) -DIARYLIMIDAZOLS
CO4810373A1 (en) ARYL-CONDENSED AZAPOLYCLIC COMPOUNDS
UY27535A1 (en) BENZAMIDA, HETEROARILAMIDA AND INVESTED AMIDAS,
ES2221183T3 (en) OXICARBAMILO COMPOUNDS THAT INHIBIT THE ADHESION OF LEUKOCYTES THROUGH VLA-4.
AR039985A1 (en) PIRIMIDINONE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE PREPARATION OF THIS LAST
CL2008002787A1 (en) Compounds derived from piperidine, which have modulating activity on the activity of the gpr 119 receptor; pharmaceutical composition comprising said compounds; and its use in the treatment of diseases such as type 1 and 2 diabetes, hyperpidemia, coronary heart disease, obesity and erectile dysfunction.
ES2088388T3 (en) MACROLID COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL MOBILITY DISORDERS.
DE602004019206D1 (en) ANTI-INFLAMMATORY MEDICINE PREPARATIONS FOR INFLAMMATORY INFLAMMATION AND THE THERAPY OR PROPHYLAXIS OF GASTRIC TOXICITY
CY1108932T1 (en) Compounds 4- (heterocyclyl) -benzenesulfoximine for the therapeutic treatment of inflammatory diseases
UY23561A1 (en) PROCEDURE FOR THE PREPARATION OF TNF-MUTEINS
CO2023000097A2 (en) Glp-1 and gip receptor coagonists suitable for oral delivery
ES2063841T3 (en) USE OF THE ACTIVE SUBSTANCE AZELASTIN TO COMBAT DISEASES OF PSORIASIS.
TR199802537T2 (en) Peptide tèrevleri.
AR004480A1 (en) ASCOMICINE COMPOUNDS HAVING ANTI-INFLAMMATORY ACTIVITY, PROCEDURE TO PREPARE THEM, USE OF SUCH COMPOUNDS TO PREPARE PHARMACEUTICAL AGENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM
DE602005022098D1 (en) 2-METHYLENE-18,19-DINOR-1ALFA-HYDROXY-HOMOPREGNACALCIFEROL AND ITS USES
MX9306494A (en) POLYPEPTIDES Ó - SUBSTITUTES THAT HAVE THERAPEUTIC ACTIVITY.